Analyst firms · Oppenheimer · NTLA

Oppenheimer NTLA price target and rating history

Intellia Therapeutics Inc. (NTLA) · Health Care

Oppenheimer rates Intellia Therapeutics Inc. (NTLA) Outperform with a $150 price target, as of its latest action on Feb 7, 2022. It has published 4 rating actions on NTLA since June 2021, including 1 upgrade and 0 downgrades.

Current rating
Outperform
Price target
$150
Median target, all firms
Too few
Actions on NTLA
4

Oppenheimer price target on NTLA

$160$143$12520222023202420252026
Oppenheimer price target on NTLA, each point a stated target, June 2021 to February 2022.

Every Oppenheimer rating on NTLA

How other firms rate NTLA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysUnderweight$8Oct 6, 2026
Wolfe ResearchUnderperform$9Jul 16, 2026
William BlairOutperformMar 2, 2026

Questions about Oppenheimer and NTLA

What is Oppenheimer's price target for NTLA?
Oppenheimer's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $150, from its action on Feb 7, 2022.
What is Oppenheimer's rating on NTLA?
Oppenheimer rates NTLA Outperform, a bullish rating, as of Feb 7, 2022.
When did Oppenheimer last change its view on NTLA?
On Feb 7, 2022, Oppenheimer upgrades to Outperform from Perform, price target $145 to $150.

More NTLA rating histories

All Oppenheimer ratingsNTLA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.